Minimal loss of lifetime for patients with diffuse large B-cell lymphoma in remission and event free 24 months after treatment: A Danish population-based study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

  • Lasse Hjort Jakobsen
  • Martin Bøgsted
  • Brown, Peter de Nully
  • Bente Arboe
  • Judit Jørgensen
  • Thomas Stauffer Larsen
  • Maja Bech Juul
  • Lene Schurmann
  • Linda Højberg
  • Olav Jonas Bergmann
  • Therese Lassen
  • Pär Lars Josefsson
  • Paw Jensen
  • Hans Erik Johnsen
  • Tarec Christoffer El-Galaly

Purpose: The general outlook for patients with diffuse large B-cell lymphoma (DLBCL) in first remission is important information for patients and for planning post-treatment follow-up. The purpose of this study was to evaluate the survival of patients with DLBCL in remission compared with a matched general population. Methods: A total of 1,621 patients from the Danish Lymphoma Registry who were newly diagnosed with DLBCL between 2003 and 2011 were included in this study. All patients were ≥ 16 years of age at diagnosis and had achieved complete remission or complete remission unconfirmed after first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or R-CHOP-like therapy. Results: The 5-year post-treatment DLBCL survival was inferior to survival in the matched general population (78%; 95% CI, 76 to 80; v 87%; standardized mortality ratio, 1.75; P < .001). Excess mortality was present but reduced for patients achieving post-treatment event-free survival for 24 months (pEFS24; standardized mortality ratio, 1.27; P < .001). In age-stratified analyses, the survival of patients < 50 years of age was normalized to the general population after achieving pEFS24 (P = .99). During the first 8 years after pEFS24, the average loss of lifetime was 0.31 mo/y (95% CI, 0.11 to 0.50 mo/y). Excess mortality diminished when analyzing death from lymphoma as competing event to death from other causes, suggesting that early and late relapse is responsible for increased mortality in patients with DLBCL. Conclusion: Although this population-based study does not support complete normalization of survival for patients with DLBCL achieving pEFS24, the estimated loss of residual lifetime was low for patients in continuous remission 2 years after ending treatment. Therefore, pEFS24 is an appealing and relevant milestone for patient counseling and could be a surrogate end point in clinical trials.

TidsskriftJournal of Clinical Oncology
Udgave nummer7
Sider (fra-til)778-784
Antal sider7
StatusUdgivet - mar. 2017

ID: 188110416